Advanced therapy medicinal products (ATMP) are medicinal products involving cells, gene therapy or tissue engineering. They are used in many different indications, such as immune diseases, Parkinson’s and Alzheimer’s disease, cartilage defects, cardiac repair, skin replacement and cancer immunotherapy. ATMP differ from other medicines. As they are based on chemical entities or are of biological / biotechnology origin, they require special legislation when it comes to market authorization. Therefore, this product class covering different new therapeutic strategies requires special knowledge and experience.
Outline of a clinical trial covering the testing of ATMP in a joint:
The goal of this phase III clinical study was to demonstrate the efficacy of an ATMP in the treatment of cartilage defects in a joint. The efficacy was evaluated by patients’ subjective assessments and physicians’ evaluations of the functional efficacy of the product. The cartilage regenerative effects as well as the safety profile were additionally assessed.
With our structured and supportive approach, our excellent communication skills with investigational sites aided by our acquired experience in trials with ATMP, SCOPE was able to maintain the initial proposed timelines despite many unforeseen challenges.
- Phase III clinical study
- Orthopaedic indication
- 100 subjects to be enrolled within 15 months, 20 sites in 5 different countries in Europe
Services provided by SCOPE:
In addition to general project management and clinical monitoring activities, we provide the following operations in the trial: budget planning and budget management, regulatory affairs, data management, EDC programming, safety management, pharmacovigilance, medical monitoring activities, statistical programming and analysis.
Due to regulatory timelines, only 10 sites were able to recruit during the first six months. Additionally, one country was unable to participate due to regulatory changes during the approval process. SCOPE had to replace seven sites during the recruitment phase of the trial. SCOPE’s success in replacing these sites was due in large part to the strong cooperation with sites of our investigator-network in already active countries. Additionally, a new country with three sites was added. The basis for this decision was founded in strategic knowledge of regulatory requirements for the country and the submission process. Another hurdle successfully handled was the unforeseen protocol update after the initial submission / approval. The initial recruitment goal was successfully met in the first half of the trial recruitment period. This was obtained despite regulatory delays that resulted in only 50% of the sites being active for the first half of the trial.